Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA3 known ✓ | P32297 | 5/20 | 0.95 |
| ▸ | CHRNB4 known ✓ | P30926 | 2/20 | 0.50 |
| ▸ | CHRNA7 known ✓ | P36544 | 2/20 | 0.50 |
| ▸ | CA2 known ✓ | P00918 | 2/20 | 0.46 |
| ▸ | HSD11B1 known ✓ | P28845 | 1/20 | 0.41 |
| ▸ | ITGB3 known ✓ | P05106 | 1/20 | 0.40 |
| ▸ | ITGA2B known ✓ | P08514 | 1/20 | 0.40 |
| ▸ | CHRNB2 | P17787 | 5/20 | 0.95 |
| ▸ | CHRNA4 | P43681 | 5/20 | 0.95 |
| ▸ | CHRNB3 | Q05901 | 3/20 | 0.95 |
| ▸ | CHRNA6 | Q15825 | 3/20 | 0.95 |
| ▸ | HPGD | P15428 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | CHKA | P35790 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8314 | 0.98 | CHRNB2 (1.00) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| Piperazine SCHEMBL28221523 | 0.95 | CHRNB2 (0.95) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| Hydrochloric Acid SCHEMBL5455311 | 0.93 | CHRNB2 (0.83) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL1706180 | 0.91 | CHRNB2 (0.87) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL26126254 | 0.90 | CHRNB2 (0.84) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL700886 | 0.90 | CHRNB2 (0.84) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL700681 | 0.90 | CHRNB2 (0.84) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| Hydrochloric Acid SCHEMBL2248932 | 0.90 | CHRNB2 (0.77) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL911091 | 0.89 | CHRNB2 (0.83) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL911817 | 0.89 | CHRNB2 (0.83) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 99 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111116514-B | Preparation method of 1-cyclopropanecarbonyl piperazine hydrochloride | 广州科锐特生物科技有限公司 | 2024-03-19 | — | — | CN | claimed |
| CN-112341580-B | Preparation method of polyacetal composition with high thermal stability | 青岛聚合利安工程技术有限公司 | 2022-11-11 | — | — | CN | claimed |
| CN-114249695-A | Novel crystal form of olaparide, preparation method and application | 齐鲁制药有限公司 | 2022-03-29 | — | — | CN | claimed |
| CN-112341580-A | Preparation method of polyacetal composition with high thermal stability | 青岛聚合利安工程技术有限公司 | 2021-02-09 | — | — | CN | claimed |
| CN-112047890-A | Preparation method of olaparib | 连云港杰瑞药业有限公司 | 2020-12-08 | — | — | CN | claimed |
| CN-109535082-A | A kind of preparation method of olaparib | 合肥创新医药技术有限公司 | 2019-03-29 | — | — | CN | claimed |
| CN-106905243-A | A kind of preparation method of olaparib | 广州仁恒医药科技股份有限公司 | 2017-06-30 | — | — | CN | claimed |
| EP-3504196-B1 | PROCESSES FOR PREPARING OLAPARIB | SCINOPHARM TAIWAN LTD (TW) | 2026-04-08 | — | — | EP | disclosed |
| EP-4163277-B1 | NOVEL PYRAZOLE DERIVATIVES | APTABIO THERAPEUTICS INC (KR) | 2026-01-14 | — | — | EP | disclosed |
| US-12459899-B2 | Isoquinolinone derivatives, method for preparing the same, and pharmaceutical composition for preventing or treating poly(ADP-ribose) polymerase-1-related diseases, comprising the same as active ingredient | DIGMBIO, Inc. (KR) | 2025-11-04 | — | — | US | disclosed |
| EP-4501920-A1 | NOVEL PYRAZOLE DERIVATIVES | Aptabio Therapeutics Inc. (KR) | 2025-02-05 | — | — | EP | disclosed |
| CN-119156379-A | Novel pyrazole derivatives | 阿普塔生物治疗公司 | 2024-12-17 | — | — | CN | disclosed |
| US-20240308983-A1 | NOVEL PYRAZOLE DERIVATIVES | APTABIO THERAPEUTICS INC (KR) | 2024-09-19 | — | — | US | disclosed |
| WO-2011000945-A2 | AMINOALKAMIDES FOR USE IN THE TREATMENT OF INFLAMMATORY, DEGENERATIVE OR DEMYELINATING DISEASES OF THE CNS | NENSIUS RESEARCH A/S (DK) | 2011-01-06 | — | — | WO | disclosed |
| US-7692006-B2 | Phthalazinone derivatives | KUDOS PHARMACEUTICALS LIMITED (GB) | 2010-04-06 | — | — | US | disclosed |
| WO-2010017055-A2 | DIHYDROPYRIDOPHTHALAZINONE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) | LEAD THERAPEUTICS, INC. (US) | 2010-02-11 | — | — | WO | disclosed |
| US-20100035883-A1 | DIHYDROPYRIDOPHTHALAZINONE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) | LEAD THERAPEUTICS, INC. (US) | 2010-02-11 | — | — | US | disclosed |
| US-20090270617-A1 | PHTHALAZINONE DERIVATIVE | KUDOS PHARMACEUTICALS LIMITED (GB) | 2009-10-29 | — | — | US | disclosed |
| CN-101528714-A | Polymorphs of 4- [ 3- (4-cyclopropanecarbonyl-piperazine-1-carbonyl) -4-fluoro-benzyl ] -2H-phthalazin-1-one | KUDOS PHARM LTD (GB) | 2009-09-09 | — | — | CN | disclosed |
| US-20080146575-A1 | 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one as crystalline; enzyme poly(ADP-ribose)polymerase (synthase)-1 or poly ADP-ribosyltransferase (PARP-1) inhibitor; anticarcinogenic with BRCA2 deficient phenotype; septic shock, ischemic injury, multiple sclerosis | KUDOS PHARMACEUTICALS LIMITED (GB) | 2008-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12459899-B2 | Isoquinolinone derivatives, method for preparing the same, and pharmaceutical composition for preventing or treating poly(ADP-ribose) polymerase-1-related diseases, comprising the same as active ingredient | PARP1, PARP2, PARP11 | CHRNA3 4324/4885CHRNB4 4598/4885CHRNA7 3906/4885 |
| US-20080146575-A1 | 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one as crystalline; enzyme poly(ADP-ribose)polymerase (synthase)-1 or poly ADP-ribosyltransferase (PARP-1) inhibitor; anticarcinogenic with BRCA2 deficient phenotype; septic shock, ischemic injury, multiple sclerosis | PARP1, PARP11, PARP2 | CHRNA3 4141/4885CHRNB4 4373/4885CHRNA7 4228/4885 |
| US-20090270617-A1 | PHTHALAZINONE DERIVATIVE | PML, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, NCOA4 | CHRNA3 3826/4885CHRNB4 3869/4885CHRNA7 4172/4885 |
| US-20100035883-A1 | DIHYDROPYRIDOPHTHALAZINONE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) | PARP1, PARP2, PARP11 | CHRNA3 4195/4885CHRNB4 4565/4885CHRNA7 4156/4885 |
| US-20240308983-A1 | NOVEL PYRAZOLE DERIVATIVES | CYP4B1, CYP3A43, CYP11B1 | CHRNA3 3475/4885CHRNB4 3694/4885CHRNA7 3659/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.